OMERS ADMINISTRATION Corp Has $576,000 Stake in Revvity, Inc. (NYSE:RVTY)

OMERS ADMINISTRATION Corp trimmed its holdings in shares of Revvity, Inc. (NYSE:RVTY - Free Report) by 94.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,157 shares of the company's stock after selling 80,787 shares during the period. OMERS ADMINISTRATION Corp's holdings in Revvity were worth $576,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of RVTY. Quarry LP grew its stake in Revvity by 45.7% in the fourth quarter. Quarry LP now owns 303 shares of the company's stock valued at $34,000 after purchasing an additional 95 shares in the last quarter. HB Wealth Management LLC grew its stake in Revvity by 4.6% in the fourth quarter. HB Wealth Management LLC now owns 2,380 shares of the company's stock valued at $266,000 after purchasing an additional 104 shares in the last quarter. Signaturefd LLC grew its stake in Revvity by 6.8% in the fourth quarter. Signaturefd LLC now owns 1,668 shares of the company's stock valued at $186,000 after purchasing an additional 106 shares in the last quarter. Westside Investment Management Inc. grew its stake in Revvity by 0.8% in the fourth quarter. Westside Investment Management Inc. now owns 14,363 shares of the company's stock valued at $1,603,000 after purchasing an additional 108 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in Revvity by 33.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company's stock valued at $58,000 after purchasing an additional 131 shares in the last quarter. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Stock Performance

NYSE:RVTY traded down $1.01 during mid-day trading on Friday, hitting $89.47. 1,023,503 shares of the company's stock traded hands, compared to its average volume of 951,592. The firm has a 50 day moving average of $96.71 and a two-hundred day moving average of $109.21. Revvity, Inc. has a 12 month low of $88.01 and a 12 month high of $129.50. The firm has a market capitalization of $10.55 billion, a price-to-earnings ratio of 40.48, a price-to-earnings-growth ratio of 3.82 and a beta of 1.02. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. The firm had revenue of $664.76 million during the quarter, compared to the consensus estimate of $662.30 million. During the same quarter in the prior year, the company earned $0.98 EPS. The firm's revenue for the quarter was up 2.3% compared to the same quarter last year. On average, equities analysts forecast that Revvity, Inc. will post 4.94 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, July 18th. This represents a $0.28 annualized dividend and a yield of 0.31%. Revvity's payout ratio is 11.91%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. The Goldman Sachs Group lowered their target price on Revvity from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, April 29th. Barclays lowered their target price on Revvity from $140.00 to $110.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. JPMorgan Chase & Co. lowered their target price on Revvity from $120.00 to $100.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 29th. Wall Street Zen downgraded Revvity from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Wells Fargo & Company lowered their target price on Revvity from $130.00 to $102.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Five investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Revvity presently has a consensus rating of "Moderate Buy" and an average target price of $125.64.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.